Guided Therapeutics Stock Analysis
| GTHP Stock | USD 0.35 0.04 10.26% |
Guided Therapeutics holds a debt-to-equity ratio of 0.6. Guided Therapeutics' financial risk is the risk to Guided Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Guided Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Guided Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Guided OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Guided Therapeutics' stakeholders.
For many companies, including Guided Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Guided Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Guided Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Guided Therapeutics' debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Guided Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Guided Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Guided Therapeutics is said to be less leveraged. If creditors hold a majority of Guided Therapeutics' assets, the OTC Stock is said to be highly leveraged.
Guided Therapeutics is overvalued with Real Value of 0.3 and Hype Value of 0.35. The main objective of Guided Therapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Guided Therapeutics is worth, separate from its market price. There are two main types of Guided Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Guided Therapeutics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Guided |
Guided OTC Stock Analysis Notes
About 40.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.19. Guided Therapeutics last dividend was issued on the 29th of March 2019. The entity had 1:800 split on the 29th of March 2019. Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.The quote for Guided Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Guided Therapeutics call Gene Cartwright at 770 242 8723 or check out https://www.guidedinc.com.Guided Therapeutics Investment Alerts
| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
Guided Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.77 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Guided Therapeutics's market, we take the total number of its shares issued and multiply it by Guided Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 19th of February, Guided Therapeutics retains the Risk Adjusted Performance of 0.0934, market risk adjusted performance of (0.57), and Downside Deviation of 14.55. Guided Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyze and collected data for nineteen technical drivers for Guided Therapeutics, which can be compared to its competitors.Guided Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Guided Therapeutics Predictive Daily Indicators
Guided Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Guided Therapeutics otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Guided Therapeutics Forecast Models
Guided Therapeutics' time-series forecasting models are one of many Guided Therapeutics' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Guided Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Guided Therapeutics Debt to Cash Allocation
Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity.Guided Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Guided Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Guided Therapeutics, which in turn will lower the firm's financial flexibility.About Guided OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Guided Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Guided shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Guided Therapeutics. By using and applying Guided OTC Stock analysis, traders can create a robust methodology for identifying Guided entry and exit points for their positions.
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Guided Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.